Moderna Inc
Healthy Returns: What we know about the next round of Covid vaccines
New vaccine COMIRNATY® (COVID-19 Vaccine, mRNA) by Pfizer, available at CVS Pharmacy in Eagle Rock, CA. Irfan Khan | Los Angeles Times | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! It’s almost that time of the year again. A new […]
Read MoreModerna’s combination Covid, flu vaccine is more effective than existing shots in late-stage trial
Empty bottles of Moderna’s Covid-19 vaccine. Fred Tanneau | AFP | Getty Images Moderna on Monday said its combination vaccine that targets both Covid-19 and the flu was more effective than existing standalone shots for those viruses in a late-stage trial. The biotech company is the first to release positive phase three data on a […]
Read MoreFDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach
A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022. Hannah Mckay | Reuters The Food and Drug Administration on Friday expanded the approval of GSK‘s respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the potentially lethal virus. The shot, called Arexvy, […]
Read MoreHealthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big
Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! I’m back in New York City after spending the last weekend in […]
Read MoreModerna, Merck say vaccine improved survival in patients with deadly skin cancer
Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck’s Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. […]
Read MoreFDA approves Moderna’s RSV vaccine for seniors, the company’s second-ever product
The FDA has approved Moderna’s RSV vaccine for older adults. Courtesy: Moderna The Food and Drug Administration on Friday approved Moderna’s vaccine for respiratory syncytial virus for adults ages 60 and above, the company’s second-ever product to enter the U.S. market. The decision is a win for Moderna, which desperately needs another revenue source amid […]
Read MoreHealthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference
Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! This is Annika, and I’ll be on the ground at the American […]
Read MoreHere’s how U.S. health officials are responding to bird flu in humans after second case
Cows are seen standing in a feedlot on June 14, 2023 in Quemado, Texas. Brandon Bell | Getty Images U.S. health officials are monitoring and preparing to combat bird flu in humans, even as they stress that the risk to the general public remains low. A strain of bird flu called H5N1 has been confirmed […]
Read MoreThe stock market gets nailed by the Fed, again. Plus, Starbucks’ quiet comeback
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Fed foils stocks : The market […]
Read MoreStocks making the biggest moves midday: Target, Urban Outfitters, Tesla, Shopify and more
Check out the companies making headlines in midday trading: Target — Shares of the retailer pulled back more than 7% after a first-quarter earnings miss , underscored by a 3% year-over-year decline in sales. Analog Devices — Stock in the semiconductor manufacturer surged more than 8% after second-quarter results beat analysts’ estimates. Massachusetts-based Analog reported […]
Read More